DC Bead (E7040) / Eisai, Boston Scientific - LARVOL DELTA

Clinical Impact and Significant Technical Points of Transarterial Chemoembolization (TACE) Using the Smaller Drug-Eluting Bead M1 (DC Bead M1™) for Hepatocellular Carcinoma: A Case Series. (PubMed, Cureus) - "DEM1-TACE had good treatment responses in patients with HCC. Evaluating retention of homogeneous contrast medium after DEM1-TACE using IVR-CT is one of the main predictors of treatment success."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™). (PubMed, Cureus) - "Morphological analysis showed that there were no significant morphological changes for each agitated time up to 30 sec compared with that observed for the beads left at room temperature. Conclusions The most convenient and effective way for reducing the loading time of epirubicin into DC Bead M1 was observed in Group D (left at room temperature for five min)."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

In vitro comparative study of multimodal imaging nano-assembled microspheres with two clinical drug-eluting beads loaded with doxorubicin. (PubMed, Drug Deliv) - "DC Beads and CalliSpheres are commonly used microspheres in clinical transcatheter arterial chemoembolization, but these microspheres cannot be visualized by themselves. The results indicate that NAMs had good drug delivery and release characteristics as well as DC Bead and CalliSpheres in vitro experimental stage. Therefore, NAMs have a good application prospect in transcatheter arterial chemoembolization treatment of hepatocellular carcinoma."

Journal • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). (PubMed, J Hepatocell Carcinoma) - "The aim of this retrospective study was to evaluate the safety and efficacy of patients with hepatocellular carcinoma treated with drug-eluting bead with doxorubicin transarterial chemoembolization (DEBDOX-TACE) in Taiwan. No hepatic encephalopathy and no procedure-related death were found. Real-world data from Taiwan demonstrated that DEBDOX-TACE for hepatocellular carcinoma can achieve high tumor response rate with low adverse events."

Journal • CNS Disorders • Gastrointestinal Cancer • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Pain • Solid Tumor

Microfluidics Platform for Studies of Peptide - Polyelectrolyte Interaction. (PubMed, Int J Pharm) - "To validate the method, microgels consisting of, respectively, covalently cross-linked hyaluronic acid, polyacrylic acid, and commercially available DC Bead™, were exposed to three model substances: cytochrome C, protamine sulfate and amitriptyline hydrochloride. These components were chosen to include systems with widely different physiochemical properties (charge, size, self-assembly, etc.) The experimental results were compared with theoretical predictions from a gel model developed earlier. The results show that the method is suitable as a rapid screening method for automated, large-scale, probing of interactions between biopolymers and drug molecules, with small consumption of material."

Journal

SBRTvsTACE: Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant (clinicaltrials.gov) - P2; N=60; Completed; Sponsor: Lahey Clinic; Active, not recruiting ➔ Completed

Clinical • Trial completion • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • Transplantation • MRI

An In Vitro Comparative Study of Three Drug-Eluting Beads Loaded with Raltitrexed. (PubMed, Cancer Biother Radiopharm) - "Background: This study aimed to investigate the raltitrexed loading method, compatible stability with contrast agent, release profiles, and morphological properties of CalliSpheres, DC Bead, and HepaSphere. The amount of drug loading could meet clinical requirements by the optimized method. All three raltitrexed-loaded DEBs showed poor compatible stability with iopamidol, as well as rapid drug release performance, which should be noticed in clinical practice."

Journal • Preclinical

[VIRTUAL] A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). (ASCO 2020) - P2 | "For early stage HCC patients with CTP Class A/B liver cirrhosis, SBRT appears as effective as TACE at controlling HCC prior to LT, may engender less toxicity, and eliminates the need for hospitalization. A larger multi-center trial is ongoing. Research Funding: Wise Grant, Pharmaceutical/Biotech Company"

Clinical • P2 data • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Pain • Solid Tumor

Traditional versus Microsphere Embolization for Hepatocellular Carcinoma: An Effectiveness Evaluation Using Data Mining. (PubMed, Healthcare (Basel)) - "There are two types: traditional ("conventional" or "cTACE") and microsphere ("DC bead TACE")...However, some of our results contradicted those elsewhere in the literature, possibly due to a relatively small sample size. Significantly larger data sets with appropriate levels of granularity could produce more accurate results."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Transarterial Chemoembolization of Hepatocellular Carcinoma with Oncozene Microspheres: An Initial, Short-Term Clinical Experience-A Retrospective, Matched, Comparison Study. (PubMed, Life (Basel)) - "Both OZ-TACE and LC-TACE had similar median progression-free survival (283 vs. 209 days; p = 0.14) and 1-year overall survival rates (85% vs. 76%; p = 0.30). With a significantly reduced dose of doxorubicin, TACE performed with Oncozene microspheres in a heterogeneous patient population is well-tolerated, safe, and produces a similar radiological response and survival rate when compared to LC Bead TACE."

Journal • Retrospective data • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Pain • Solid Tumor

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - P2; N=14; Completed; Sponsor: Yale University; Recruiting ➔ Completed; N=20 ➔ 14

Clinical • Enrollment change • Trial completion • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CEACAM5

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC (clinicaltrials.gov) - P=N/A; N=20; Not yet recruiting; Sponsor: Universitaire Ziekenhuizen Leuven

Clinical • Combination therapy • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Sidney Kimmel Comprehensive Cancer Center

Clinical • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CEACAM5

Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Sidney Kimmel Comprehensive Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CEACAM5

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC (clinicaltrials.gov) - P=N/A; N=0; Withdrawn; Sponsor: Universitaire Ziekenhuizen Leuven; N=20 ➔ 0; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Oct 2013 ➔ Dec 2014

Clinical • Combination therapy • Enrollment change • Trial primary completion date • Trial withdrawal • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

CIREL: CIRSE Registry for LifePearl Microspheres (clinicaltrials.gov) - P=N/A; N=152; Active, not recruiting; Sponsor: Cardiovascular and Interventional Radiological Society of Europe; Recruiting ➔ Active, not recruiting; Trial primary completion date: Sep 2020 ➔ Aug 2021

Enrollment closed • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

"#UniversalWisdom regardless of religious beliefs #GreatPerson #Integrity #Decency #MahatmaGandhi #LifePearls @MinnowWalsh @LucySafi @Dr_DanMD @BethFratesMD @Mustapja @FadiSaab17 @DBelardoMD @DLBHATTMD @RhianEDavies1 @Allison_Dupont @a_l_bailey @HeartOTXHeartMD @hvanspall" (@HadyLichaaMD)

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (clinicaltrials.gov) - P2; N=22; Not yet recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2022 ➔ Dec 2023

Clinical • Trial completion date • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

[VIRTUAL] Safety, tolerability and efficacy of transarterial chemoembolization using anthracyclines-loaded drug eluting microspheres for treatment of patients with unresectable hepatocellular carcinoma: Pooled analyses. (ASCO-GI 2021) - "The treatment of patients with unresectable HCC with anthracycline loaded LifePearl showed good tolerance with acceptable toxicity and high tumor response rate that translated into promising PFS, TTUP and OS."

Clinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. (PubMed, Cancers (Basel)) - P=N/A | "DEM-TACE using LifePearl provides a high tumor response rate in HCC patients. HBT rates within or below previously reported results for cTACE and DEM-TACE indicate a good safety profile for LifePearl. The trial was registered in ClinicalTrials.gov National Library of Medicine (ID: NCT03053596)."

Clinical • Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

LIVERPEARL: Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (clinicaltrials.gov) - P2; N=48; Not yet recruiting; Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo

Clinical • Combination therapy • New P2 trial • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P3; N=400; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Sep 2020 ➔ Dec 2020

Clinical • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Psychiatry • Solid Tumor

[VIRTUAL] ACUTE LUNG INJURY FOLLOWING TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION WITH DRUG ELUTING BEADS LOADED WITH DOXORUBICIN (CHEST 2020) - "She was started on prednisone for presumed TACE-induced pneumonitis and was discharged with home oxygen and follow-up with pulmonology...We described a case of acute lung injury three days after TACE with doxorubicin-eluting beads (DEB-TACE). Although an unusual complication, this entity will be more important given the increasing prevalence of DEB-TACE."

Acute Lung Injury • CNS Disorders • Fatigue • Fibrosis • Gall Bladder Cancer • Gastrointestinal Cancer • Hepatitis C Virus • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Interstitial Lung Disease • Liver Failure • Oncology • Pain • Palliative care • Pneumonia • Respiratory Diseases • Solid Tumor

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. (PubMed, Cardiovasc Intervent Radiol) - P=N/A | "This interim analysis confirms in a prospective analysis the feasibility of the study, with an acceptable toxicity profile. More patients reported a stable or improved HRQOL than deterioration. Deterioration of HRQOL was seen especially in salvage therapy patients."

Clinical • Journal • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

SBRTvsTACE: Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant (clinicaltrials.gov) - P2; N=60; Active, not recruiting; Sponsor: Lahey Clinic; Trial primary completion date: Jul 2020 ➔ Oct 2021

Clinical • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • Transplantation